Literature DB >> 28642265

The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter.

Y S Choi1, S S Ahn1, H-J Lee1, J H Chang2, S-G Kang2, E H Kim2, S H Kim3, S-K Lee4.   

Abstract

BACKGROUND AND
PURPOSE: Although perfusion and permeability MR parameters have known to have prognostic value, they have reproducibility issues. Our aim was to evaluate whether the initial area under the time-to-signal intensity curve (IAUC) derived from dynamic contrast-enhanced MR imaging can improve prognosis prediction in patients with glioblastoma with known MGMT status.
MATERIALS AND METHODS: We retrospectively examined 88 patients with glioblastoma who underwent preoperative dynamic contrast-enhanced MR imaging. The means of IAUC values at 30 and 60 seconds (IAUC30mean and IAUC60mean) were extracted from enhancing tumors. The prognostic values of IAUC parameters for overall survival and progression-free survival were assessed with log-rank tests, according to the MGMT status. Multivariate overall survival and progression-free survival models before and after adding the IAUC parameters as covariates were explored by net reclassification improvement after receiver operating characteristic analysis for 1.5-year overall survival and 1-year progression-free survival and by random survival forest.
RESULTS: High IAUC parameters were associated with worse overall survival and progression-free survival in the unmethylated MGMT group, but not in the methylated group. In the unmethylated MGMT group, 1.5-year overall survival and 1-year progression-free survival prediction improved significantly after adding IAUC parameters (overall survival area under the receiver operating characteristic curve, 0.86; progression-free survival area under the receiver operating characteristic curve, 0.74-0.76) to the model with other prognostic factors (overall survival area under the receiver operating characteristic curve, 0.81; progression-free survival area under the receiver operating characteristic curve, 0.69; P < .05 for all) except in the case of IAUC60mean for 1-year progression-free survival prediction (P = .059). Random survival forest models indicated that the IAUC parameters were the second or most important predictors in the unmethylated MGMT group, except in the case of the IAUC60mean for progression-free survival.
CONCLUSIONS: IAUC can be a useful prognostic imaging biomarker in patients with glioblastoma with known MGMT status, improving prediction of glioblastoma prognosis with the unmethylated MGMT promoter status.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28642265      PMCID: PMC7960440          DOI: 10.3174/ajnr.A5265

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.

Authors:  Yoon Seong Choi; Ho-Joon Lee; Sung Soo Ahn; Jong Hee Chang; Seok-Gu Kang; Eui Hyun Kim; Se Hoon Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2016-07-19       Impact factor: 5.315

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

3.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.

Authors:  Eric S Paulson; Kathleen M Schmainda
Journal:  Radiology       Date:  2008-09-09       Impact factor: 11.105

4.  Improved correlation to quantitative DCE-MRI pharmacokinetic parameters using a modified initial area under the uptake curve (mIAUC) approach.

Authors:  Hai-Ling Margaret Cheng
Journal:  J Magn Reson Imaging       Date:  2009-10       Impact factor: 4.813

5.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

Authors:  Jayant Narang; Rajan Jain; Ali Syed Arbab; Tom Mikkelsen; Lisa Scarpace; Mark L Rosenblum; David Hearshen; Abbas Babajani-Feremi
Journal:  Neuro Oncol       Date:  2011-07-29       Impact factor: 12.300

6.  Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Authors:  M A Prah; S M Stufflebeam; E S Paulson; J Kalpathy-Cramer; E R Gerstner; T T Batchelor; D P Barboriak; B R Rosen; K M Schmainda
Journal:  AJNR Am J Neuroradiol       Date:  2015-06-11       Impact factor: 3.825

7.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Meng Law; Robert J Young; James S Babb; Nicole Peccerelli; Sophie Chheang; Michael L Gruber; Douglas C Miller; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  Radiology       Date:  2008-03-18       Impact factor: 11.105

8.  Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.

Authors:  Yoon Seong Choi; Sung Soo Ahn; Dong Wook Kim; Jong Hee Chang; Seok-Gu Kang; Eui Hyun Kim; Se Hoon Kim; Tyler Hyungtaek Rim; Seung-Koo Lee
Journal:  Radiology       Date:  2016-04-27       Impact factor: 11.105

9.  Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.

Authors:  Won Jung Chung; Ho Sung Kim; Namkug Kim; Choong Gon Choi; Sang Joon Kim
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

10.  Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Authors:  Monika E Hegi; Annie-Claire Diserens; Sophie Godard; Pierre-Yves Dietrich; Luca Regli; Sandrine Ostermann; Philippe Otten; Guy Van Melle; Nicolas de Tribolet; Roger Stupp
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  4 in total

1.  Dynamic Contrast-Enhanced MRI in Patients with Brain Metastases Undergoing Laser Interstitial Thermal Therapy: A Pilot Study.

Authors:  J I Traylor; D C A Bastos; D Fuentes; M Muir; R Patel; V A Kumar; R J Stafford; G Rao; S S Prabhu
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

Review 2.  Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

Authors:  Whitney B Pope; Garth Brandal
Journal:  Q J Nucl Med Mol Imaging       Date:  2018-04-26       Impact factor: 2.346

3.  A new bioinformatics approach identifies overexpression of GRB2 as a poor prognostic biomarker for prostate cancer.

Authors:  Teppei Iwata; Anna S Sedukhina; Manabu Kubota; Shigeko Oonuma; Ichiro Maeda; Miki Yoshiike; Wataru Usuba; Kimino Minagawa; Eleina Hames; Rei Meguro; Sunny Cho; Stephen H H Chien; Shiro Urabe; Sookhee Pae; Kishore Palanisamy; Toshio Kumai; Kazuo Yudo; Eiji Kikuchi; Ko Sato
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

Review 4.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.